Overview on recent developments in phage clinical trials – BiomX BX002, Adaptive Phage Therapeutics DANCE, Locus Biosciences LBP-EC001 and NIAID with ARLG WRAIR-PAM-CF1.
Creative Biolabs shares insights on bacteriophage therapy to treat acne caused by specific strains of Cutibacterium acnes.
Creative Biolabs shares an outlook on the use of bacteriophages as a Tuberculosis diagnostic tool for the detection of TB infection.
Developments surrounding phage therapy in Australia have been approved to regulate the process of phage therapy, rather than a specific phage product.
ACD Pharma, a Norwegian research and development company, is constructing the first world’s large-scale phage production plant.
Creative Biolabs shares research on unmodified bacteriophages against Shigella flexneri, focusing on the use of natural phages to treat dysentery.
Anna Dragoš receives funding from the European Research Council (ERC) for the project PHAGECONTROL – The evolution of host manipulation by bacteriophage.
The battle against SARS-CoV-2 has presented the potential for the use of phage therapy for Covid19 rehabilitation of post-Covid19 patients.
TechnoPhage announces the first Clinical Safety results of the Innovative Biological product TP-102 against diabetic foot infections (DFI).